PharmaGap Inc. has developed novel drugs targeting Protein Kinase C (PKC). The Company’s pre-clinical lead drug candidate (GAP-107B8) is being developed to treat cancer. Aberrant over-expression of PKC is associated with many types of cancer and is a validated therapeutic target. 

GAP-107B8 was developed employing proprietary computer models PharmaGap researchers have developed for select PKC isoforms. PharmaGap’s computer modeling abilities are a core competency and form the basis for the Company’s intellectual property and pipeline of drug compounds targeting PKC for the treatment of cancer and other diseases.

PharmaGap is pursuing a strategy to partner its lead drug candidates at the pre-clinical or early clinical trial stage.  The Company recognizes that its strengths rest in drug design and “proof of principle” validation and that larger pharmaceutical/biotech partners have the resources necessary to move the Company’s compounds into human clinical use.

PharmaGap is a spin-out from Canada’s premier biological research organization, the National Research Council of Canada. Offices and labs are located in Ottawa, Ontario, Canada.

PharmaGap will be attending BioPartnering North America in January 2010.  Please contact simon.goulet@pharmagap.com to request a meeting at the conference.